WT1 and acute myeloid leukemia: concluded that integrating cytogenetic risk at diagnosis with MRD assessment using both flow cytometry and WT1 allowed for better classification of AML patients: into three prognostic groups: good (no-high risk features “HR” and flow-MRD-ve), intermediate (no-HR, flow-MRD+ve and WT1 ≥2 log) and adverse prognosis (HR or WT1 < 2 log) with a 3-year DFS of 78.8%, 51.6% and 0%, respectively, p<.001) (24).